This study provides new ideas for personalized treatment of bladder cancer patients, but the lack of specific inhibitors for OTUD5 does not allow an in-depth analysis of the therapeutic effects of OTUD5 inhibitors combined with everolimus. This evidence concerns the gene OTUD5 and urinary bladder carcinoma.